1. Home
  2. BLNK vs ZURA Comparison

BLNK vs ZURA Comparison

Compare BLNK & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blink Charging Co.

BLNK

Blink Charging Co.

HOLD

Current Price

$0.63

Market Cap

113.9M

ML Signal

HOLD

Logo Zura Bio Limited

ZURA

Zura Bio Limited

HOLD

Current Price

$5.12

Market Cap

455.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLNK
ZURA
Founded
2009
2022
Country
United States
United States
Employees
N/A
40
Industry
Industrial Specialties
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
113.9M
455.4M
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
BLNK
ZURA
Price
$0.63
$5.12
Analyst Decision
Buy
Buy
Analyst Count
4
6
Target Price
$2.33
$13.00
AVG Volume (30 Days)
2.3M
1.7M
Earning Date
05-08-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
61.22
N/A
EPS
N/A
N/A
Revenue
$126,197,000.00
N/A
Revenue This Year
$5.71
N/A
Revenue Next Year
$19.65
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.45
$1.26
52 Week High
$2.65
$7.25

Technical Indicators

Market Signals
Indicator
BLNK
ZURA
Relative Strength Index (RSI) 42.14 59.46
Support Level $0.63 $4.22
Resistance Level $0.73 $5.82
Average True Range (ATR) 0.04 0.46
MACD 0.00 0.20
Stochastic Oscillator 52.40 66.40

Price Performance

Historical Comparison
BLNK
ZURA

About BLNK Blink Charging Co.

Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from the U.S.A.

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

Share on Social Networks: